Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis

Qu, Wenchun; Wang, Zhen; Engelberg-Cook, Erica; Yan, Dan; Siddik, Abu Bakar; Bu, Guojun; Allickson, Julie; Kubrova, Eva; Caplan, Arnold I.; Hare, Joshua M.; Ricordi, Camillo; Pepine, Carl J.; Kurtzberg, Joanne; Pascual, Jorge M.; Mallea, Jorge M.; Rodríguez, Ricardo López; Nayfeh, Tarek; Saadi, Samer; Durvasula, Ravindra V; Richards, Elaine M.; March, Keith L.; Sanfilippo, Fred

doi:10.1093/stcltm/szac032

Cited by 14 publications

(18 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is still a significant risk of death in the 20% of patients who develop severe COVID-19 or even acute respiratory distress syndrome (ARDS) ( 41 ). There is evidence that MSC cell therapy has the potential to reduce all-cause mortality and improve pulmonary function ( 42 ). UC-MSC is thought to have stronger angiogenic ( 43 ) and immunomodulatory properties ( 44 ), which may be more relevant to COVID-19-induced pulmonary damage and dysregulated immune response.…”

Section: Discussionmentioning

confidence: 99%

“…First, although this analysis supported that UC-MSC therapy reduces mortality in patients with severe COVID-19, it was important to note that SARS-CoV-2 Variants of Interest (VOIs) were not involved in our included studies, so it was not known whether UC-MSC had a therapeutic effect on VOIs as well. In addition, The conclusions were drawn from a comparison of UC-MSC with earlier standard care and did not take into account new treatments and vaccinations ( 55 ). Recently, numerous studies had confirmed that vaccination reduces mortality in patients with COVID-19 ( 56 ), and further validation is needed to determine whether the vaccine interacts with UC-MCS therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

ObjectivesA major challenge for COVID-19 therapy is dysregulated immune response associated with the disease. Umbilical cord mesenchymal stromal cells (UC-MSCs) may be a promising candidate for COVID-19 treatment owing to their immunomodulatory and anti-inflammatory functions. Therefore, this study aimed to evaluate the effectiveness of UC-MSCs inpatients with COVID-19.MethodMedline, Embase, PubMed, Cochrane Library, and Web of Science databases were searched to collect clinical trials concerning UC-MSCs for the treatment of COVID-19. After literature screening, quality assessment, and data extraction, a systematic review and meta-analysis of the included study were performed.ResultsThis systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022304061. After screening, 10 studies involving 293 patients with COVID-19 were eventually included. Our meta-analysis results showed that UC-MSCs can reduce mortality (relative risk [RR] =0.60, 95% confidence interval [CI]: [0.38, 0.95], P=0.03) in COVID-19 patients. No significant correlation was observed between adverse events and UC-MSC treatment (RR=0.85, 95% CI: [0.65, 1.10], P=0.22; RR=1.00, 95%CI: [0.64, 1.58], P=1.00). In addition, treatment with UC-MSCs was found to suppress inflammation and improve pulmonary symptoms.ConclusionsUC-MSCs hold promise as a safe and effective treatment for COVID-19.Systematic Review RegistartionPROSPERO, identifier CRD42022304061

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One such use that has been rapidly expanding has been the use of MSCs on patients recovering from COVID-19. Similar to the use of MSCs in autoimmune diseases, those suffering from COVID-19 had no adverse effects from cell transplantation and also had improved lung function, likely resulting from an attenuation of the cytokine storm post SARS-CoV-2 infection [98,99]. Therefore, it may be feasible to ultimately develop a standardized MSC therapy for subgroups of patients, as more studies involving cohorts with defined age and sex information, as well as standardized molecular and cellular measurements, emerge.…”

Section: Discussionmentioning

confidence: 99%

Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source

Carp

Liang

2022

Cells

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) hold great promise for the treatment of autoimmune conditions given their immunomodulatory properties. Based on the low immunogenicity of MSCs, it is tempting to consider the expansion of MSCs from a “universal donor” in culture prior to their allogeneic applications for immediate care. This raises the critical question of the criteria we should use to select the best “universal donor”. It is also imperative we compare the “universal” approach with a “personalized” one for clinical value. In addition to the call for MHC-matching, recent studies suggest that factors including age, sex, and biological sources of MSCs can have significant impact on therapy outcome. Here, we will review findings from these studies, which shed light on the variables that can guide the important choice of “universal” or “personalized” MSC therapy for autoimmune diseases.

show abstract

“…[ 147 ] Lastly, clinical trials carried out lack a single standard methodology to be compared with each other. [ 126b,148 ] Despite these drawbacks, these studies hold promise for MSCs as a therapeutic option for the management of COVID‐19‐induced T1DM and T2DM.…”

Section: Mesenchymal Stem Cell‐based Therapeutic Interventions For Th...mentioning

confidence: 99%

Dissecting the Interrelationship between COVID‐19 and Diabetes Mellitus

2023

View full text Add to dashboard Cite

COVID‐19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has led to enormous morbidity and mortality worldwide. After gaining entry into the human host, the virus initially infects the upper and lower respiratory tract, subsequently invading multiple organs, including the pancreas. While on one hand, diabetes mellitus (DM) is a significant risk factor for severe COVID‐19 infection and associated death, recent reports have shown the onset of DM in COVID‐19‐recovered patients. SARS‐CoV‐2 infiltrates the pancreatic islets and activates stress response and inflammatory signaling pathways, impairs glucose metabolism, and consequently leads to their death. Indeed, the pancreatic autopsy samples of COVID‐19 patients reveal the presence of SARS‐CoV‐2 particles in β‐cells. The current review describes how the virus enters the host cells and activates an immunological response. Further, it takes a closer look into the interrelationship between COVID‐19 and DM with the aim to provide mechanistic insights into the process by which SARS‐CoV‐2 infects the pancreas and mediates dysfunction and death of endocrine islets. The effects of known anti‐diabetic interventions for COVID‐19 management are also discussed. The application of mesenchymal stem cells (MSCs) as a future therapy for pancreatic β‐cells damage to reverse COVID‐19‐induced DM is also emphasized.

show abstract

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis

Cited by 14 publications

References 91 publications

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis

Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source

Dissecting the Interrelationship between COVID‐19 and Diabetes Mellitus

Contact Info

Product

Resources

About